Evidence map›Paper›PMID 39655338›Full record

ReviewTherapeutic advances in pulmonary and critical care medicine

Bronchiectasis-COPD Overlap Syndrome: A Comprehensive Review of its Pathophysiology and Potential Cardiovascular Implications.

Mohammad Ajaz Alam, Padmavathi Mangapuram, Fremita Chelsea Fredrick, Bhupinder Singh, Amishi Singla, Avi Kumar, Rohit Jain

Abstract readReview
In one paragraph

Review in Therapeutic advances in pulmonary and critical care medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Precise pathogen detection and clinical characterization of bronchiectasis.Frontiers in cellular and infection microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohammad Ajaz AlamAvalon University School of Medicine, Willemstad, Curacao.
Padmavathi MangapuramAvalon University School of Medicine, Willemstad, Curacao.ORCID https://orcid.org/0009-0009-4937-3629
Fremita Chelsea FredrickAvalon University School of Medicine, Willemstad, Curacao.ORCID https://orcid.org/0009-0002-3341-7251
Bhupinder SinghIcahn School of Medicine at Mount Sinai, NYC Health+Hospitals, Queens, NY, USA.
Amishi SinglaDallastown Area High School, Dallastown, PA, USA.
Avi KumarDepartment of Pulmonary Medicine, Fortis Escorts Heart Institute, Okhla, Delhi, India.
Rohit JainDepartment of Internal Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.ORCID https://orcid.org/0000-0002-9101-2351

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bronchiectasis-Chronic Obstructive Pulmonary Disease Overlap Syndrome (BCOS) is a complex pulmonary condition that merges bronchiectasis and chronic obstructive pulmonary disease (COPD), presenting unique clinical challenges. Patients with BCOS typically exhibit a range of symptoms from both conditions, including a chronic productive cough, reduced lung function, frequent exacerbations, and diminished exercise tolerance. The etiology of BCOS involves multiple factors such as genetic predisposition, respiratory infections, tobacco smoke, air pollutants, and other inflammatory mediators. Accurate diagnosis requires a comprehensive approach, incorporating pulmonary function tests to evaluate airflow limitation, radiographic imaging to identify structural lung abnormalities, and blood eosinophil counts to detect underlying inflammation. Treatment strategies are tailored to individual symptom profiles and severity, potentially including bronchodilators, inhaled corticosteroids, and pulmonary therapy to improve lung function and quality of life. Patients with BCOS are also at an increased risk for cardiovascular complications, such as stroke, ischemic heart disease, and cor pulmonale. Additionally, medications like beta-agonists and muscarinic antagonists used in COPD treatment can further affect cardiac risk by altering heart rate. This paper aims to provide a thorough understanding of BCOS, addressing its development, diagnosis, treatment, and associated cardiovascular complications, to aid healthcare providers in managing this multifaceted condition and improving patient outcomes.

Indexed as

alpha 1 antitrypsinaspergillus fumigatusbronchiectasischronic obstructive lung diseasehypoxic vasoconstrictioninflammatory mediatorspseudomonas aeruginosapulmonary hypertensiontobacco exposurevascular remodeling

Identifiers

PMID39655338
PMCPMC11626662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.